• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Aravive Inc.

    1/29/24 4:15:35 PM ET
    $ARAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email
    S-8 POS 1 arav20240128e_s8pos.htm FORM S-8 POS arav20240128e_s8pos.htm

    As filed with the Securities and Exchange Commission on January 29, 2024

    Registration No. 333-271335

    333-264445

    333-254400

    333-237425

    333-233866

    333-230348

    333-227865

    333-216586

    333-210013

    333-204178

    333-194949

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-271335

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-264445

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-254400

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-237425

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-233866

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-230348

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-227865

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-216586

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-210013

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-204178

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-194949

     

    UNDER THE SECURITIES ACT OF 1933

     

    ARAVIVE, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    26-4106690

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    River Oaks Tower

    3730 Kirby Drive, Suite 1200

    Houston, Texas 77098

    (Address, including zip code, of principal executive offices)

     

     

     

     

    Aravive, Inc. 2019 Equity Incentive Plan

    Aravive, Inc. 2014 Equity Incentive Plan

    Aravive, Inc. 2014 Employee Stock Purchase Plan

    Versartis, Inc. 2014 Equity Incentive Plan

    Versartis, Inc. 2014 Employee Stock Purchase Plan

    Versartis, Inc. 2009 Stock Plan

    (Full title of the plans)

     

    Gail McIntyre

    Secretary and Authorized Officer

    River Oaks Tower

    3730 Kirby Drive, Suite 1200

    Houston, Texas 77098

    (936) 355-1910

    (Name, address of and telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

     

     

     

    EXPLANATORY NOTE

     

    On January 17, 2024, Aravive, Inc. (the “Company”) announced its intention to voluntarily terminate the listing of its shares of common stock, par value $0.0001 per share (the “Common Stock”) from the Nasdaq Global Select Market (the “Delisting”). On October 2, 2023, at the Company’s 2023 Annual Meeting of Stockholders, the Company’s stockholders approved the transfer of all or substantially all of the Company's assets through an assignment for the benefit of creditors (the “Assignment”) if the Company’s Board of Directors (the “Board”) deemed such transfer to be in the best interests of the Company, which Assignment the Board approved on January 12, 2024. The Company subsequently filed a Form 25 with the Securities and Exchange Commission (the “SEC”) in connection with the Delisting. In connection with the foregoing and the undertakings in the Registration Statements (as defined below), the Company is hereby filing this Post-Effective Amendment to each of the Company’s registration statements on Form S-8 (Registration Nos. 333-271335, 333-264445, 333-254400, 333-237425, 333-233866, 333-230348, 333-227865, 333-216586, 333-210013, 333-204178 and 333-194949) (collectively, the “Registration Statements”) to terminate the effectiveness of each such Registration Statement and to remove from registration all of the Company’s securities that remain unsold under each such Registration Statement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on or before January 29, 2024.

     

      ARAVIVE, INC.  
         
         
      By:  /s/ Gail McIntyre  
      Gail McIntyre  
      Secretary and  
      Authorized Officer  

     

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to the Registration Statements.

     

     

     
    Get the next $ARAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAV

    DatePrice TargetRatingAnalyst
    4/17/2023$12.00Buy
    BTIG Research
    6/3/2022$15.00Buy
    ROTH Capital
    More analyst ratings

    $ARAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aravive, Inc. to Delist from The Nasdaq Stock Market

      HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market ("Nasdaq")  and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and suspend its public reporting obligations. As previously disclosed, at the Company's 2023 annual stockholder's meeting, the stockholders of the Company approved effecting a transfer and assignment of all or substantially all of the Company's assets to an assignee for the benefit

      1/17/24 4:09:41 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

      Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any differen

      8/2/23 4:01:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

      HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC). Presentation Details: Title:Phase 1b/2 Study of Batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in Combination with Cabozantinib (Cabo)

      7/28/23 7:05:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Aravive Appoints Carolina Petrini as Chief Commercial Officer

      HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company's new Chief Commercial Officer effective April 10, 2023. Ms. Petrini brings over two decades of experience in developing pre-commercial, launch readiness and commercial strategies, building and leading high-performing commercial teams. "We are delighted to welcome Carolina as our new Chief Commercial Officer," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "With her extensive experience in oncology and exception

      4/11/23 7:05:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iTolerance, Inc. Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members

      Establishment of Strategic Advisory Board provides renowned business development, clinical and regulatory leadership and expertise as iTolerance advances its proprietary technologies enabling tissue, organoid or cell therapy without the need for life-long immunosuppressionMIAMI, FL / ACCESSWIRE / January 23, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced the formation of its Strategic Advisory Board and appointments of Wayne Pines, Sigurd Kirk, and Dr. Khemraj Hirani as its inaugural members."The establishm

      1/23/23 11:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

      HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer. Dr. Geller is a medical oncologist with over 30 years of drug development experience leading all aspects of clinical and medical affairs, including commercialization preparedness and launch of novel therapeutics. Dr. Geller will play a critical role in progressing Aravive's portfolio of programs in ovarian, renal and pancreatic cancers. "Dr. Geller is a great addition to the management team as we near completion of the gl

      7/5/22 9:07:03 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aravive Inc. (Amendment)

      SC 13G/A - Aravive, Inc. (0001513818) (Subject)

      2/14/24 4:21:51 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aravive Inc. (Amendment)

      SC 13G/A - Aravive, Inc. (0001513818) (Subject)

      2/14/24 10:24:11 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aravive Inc. (Amendment)

      SC 13G/A - Aravive, Inc. (0001513818) (Subject)

      2/9/24 5:14:55 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Petrini Maria Carolina

      4 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:42 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Petrini Maria Carolina

      3 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcintyre Gail Frances

      4 - Aravive, Inc. (0001513818) (Issuer)

      2/2/23 4:25:16 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research resumed coverage on Aravive with a new price target

      BTIG Research resumed coverage of Aravive with a rating of Buy and set a new price target of $12.00

      4/17/23 9:01:46 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Aravive with a new price target

      ROTH Capital initiated coverage of Aravive with a rating of Buy and set a new price target of $15.00

      6/3/22 9:00:32 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Aravive with a new price target

      BTIG Research initiated coverage of Aravive with a rating of Buy and set a new price target of $26.00

      3/15/21 8:09:54 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Financials

    Live finance-specific insights

    See more
    • Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma

      7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor decrease from baselineBatiraxcept has been well-tolerated with no dose-limiting toxicitiesConference call and webcast today at 8:30 a.m. ET HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patie

      11/12/21 7:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

      3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (

      11/9/21 8:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Aravive Inc.

      15-12G - Aravive, Inc. (0001513818) (Filer)

      2/8/24 7:00:50 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:24 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:15 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care